Steady-state concentration of venlafaxine enantiomers: Model-based analysis of between-patient variability

European Journal of Clinical Pharmacology

Volumn 58, Issue 5, 2002, Pages 323-331

  Gex Fabry, Marianne ^a   Rudaz, Serge ^b   Balant Gorgia, Androniki E ^a   Brachet, Anne ^b   Veuthey, Jean Luc ^b   Balant, Luc P ^a   Bertschy, Gilles ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Interindividual variability; Stereoselective metabolism; Venlafaxine

Indexed keywords

CREATININE; DESVENLAFAXINE; VENLAFAXINE;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG MONITORING; ENANTIOMER; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; STEADY STATE; STEREOCHEMISTRY; THEORETICAL MODEL; WEIGHT;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036373778     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0473-2     Document Type: Article

References (36)

1. Antidepressant options: Venlafaxine in perspective
2. Drug-drug interactions involving antidepressants: Focus on venlafaxine
3. Dose-response relationship with venlafaxine
4. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression
5. Neurobiologic basis of antidepressant safety profiles
6. Venlafaxine serum levels and CYP2D6 genotype
7. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants
8. Venlafaxine oxidation in vitro is catalysed by CYP2D6
9. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative
10. A new depression scale designed to be sensitive to change
11. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics
12. Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in clinical samples by capillary electrophoresis using charged cyclodextrins
13. Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects
14. Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects
15. Estimation of creatinine clearance in patients with metastatic ovarian cancer
16. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes
17. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients
18. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism
19. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography
20. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
21. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine
22. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
23. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: A case report
24. Pharmacological importance of stereochemical resolution of enantiomeric drugs
25. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin
26. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
27. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
28. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans
29. The effects of age and gender on the stereoselective pharmacokinetics of verapamil
30. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping
31. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences
32. Gender-related differences in pharmacokinetics and their clinical significance
33. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
34. Evidence of the dual mechanisms of action of venlafaxine